Synthesis, antiviral activity, and pharmacokinetic evaluation of P3 pyridylmethyl analogs of oximinoarylsulfonyl HIV-1 protease inhibitors
- PMID: 16504523
- DOI: 10.1016/j.bmc.2006.02.013
Synthesis, antiviral activity, and pharmacokinetic evaluation of P3 pyridylmethyl analogs of oximinoarylsulfonyl HIV-1 protease inhibitors
Abstract
As a continuation of the recently communicated discovery of oximinoarylsulfonamides as potent inhibitors of HIV-1 aspartyl protease, compounds bearing pyridylmethyl substituents at P3 were designed and synthesized. Potent analogs in this series provided low single-digit nanomolar EC50 values against both wild-type HIV and resistant mutant virus (A17), attenuated some 3- to 12-fold in the presence of 50% human serum. Pharmacokinetic results for compounds in this series showed good to excellent exposure when co-administered orally with an equal amount of ritonavir (5mg/kg each) in the rat, with average AUC >8 microg h/mL. Similar dosing in dog resulted in significantly lower plasma levels (average AUC <2 microg h/mL). The 3-pyridylmethyl analog 30 gave the best overall exposure (rat AUC=7.1 microg h/mL and dog AUC=4.9 microg h/mL), however, this compound was found to be a potent inhibitor of cytochrome P450 3A (Ki=2.4 nM).
Similar articles
-
Oximinoarylsulfonamides as potent HIV protease inhibitors.Bioorg Med Chem Lett. 2005 May 2;15(9):2275-8. doi: 10.1016/j.bmcl.2005.03.008. Bioorg Med Chem Lett. 2005. PMID: 15837308
-
Lysine sulfonamides as novel HIV-protease inhibitors: Nepsilon-acyl aromatic alpha-amino acids.Bioorg Med Chem Lett. 2006 Jul 1;16(13):3459-62. doi: 10.1016/j.bmcl.2006.04.011. Epub 2006 Apr 27. Bioorg Med Chem Lett. 2006. PMID: 16644213
-
Synthesis and evaluation of inhibitors of cytochrome P450 3A (CYP3A) for pharmacokinetic enhancement of drugs.Bioorg Med Chem Lett. 2009 Sep 15;19(18):5444-8. doi: 10.1016/j.bmcl.2009.07.118. Epub 2009 Jul 30. Bioorg Med Chem Lett. 2009. PMID: 19679477
-
Structure-based discovery of Tipranavir disodium (PNU-140690E): a potent, orally bioavailable, nonpeptidic HIV protease inhibitor.Biopolymers. 1999;51(1):51-8. doi: 10.1002/(SICI)1097-0282(1999)51:1<51::AID-BIP6>3.0.CO;2-U. Biopolymers. 1999. PMID: 10380352 Review.
-
[Current status of HIV protease inhibitors].Yao Xue Xue Bao. 2005 May;40(5):389-94. Yao Xue Xue Bao. 2005. PMID: 16220778 Review. Chinese. No abstract available.
Cited by
-
Protease inhibitors from marine venomous animals and their counterparts in terrestrial venomous animals.Mar Drugs. 2013 Jun 14;11(6):2069-112. doi: 10.3390/md11062069. Mar Drugs. 2013. PMID: 23771044 Free PMC article. Review.
-
Tetrahydrofuran, tetrahydropyran, triazoles and related heterocyclic derivatives as HIV protease inhibitors.Future Med Chem. 2011 Jul;3(9):1181-97. doi: 10.4155/fmc.11.68. Future Med Chem. 2011. PMID: 21806380 Free PMC article. Review.
-
Recent Progress in the Development of HIV-1 Protease Inhibitors for the Treatment of HIV/AIDS.J Med Chem. 2016 Jun 9;59(11):5172-208. doi: 10.1021/acs.jmedchem.5b01697. Epub 2016 Jan 22. J Med Chem. 2016. PMID: 26799988 Free PMC article. Review.
-
Design and synthesis of HIV-1 protease inhibitors incorporating oxazolidinones as P2/P2' ligands in pseudosymmetric dipeptide isosteres.J Med Chem. 2007 Sep 6;50(18):4316-28. doi: 10.1021/jm070284z. Epub 2007 Aug 16. J Med Chem. 2007. PMID: 17696512 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials
